Thermo Fisher Scientific Inc Asset Resilience Ratio
Thermo Fisher Scientific Inc asset resilience ratio. Thermo Fisher Scientific Inc (TMO) has an Asset Resilience Ratio of 1.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Thermo Fisher Scientific Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Thermo Fisher Scientific Inc (1995–2024)
Asset resilience ratio of Thermo Fisher Scientific Inc from 1995 to 2024. This chart shows how Thermo Fisher Scientific Inc's Asset Resilience Ratio has changed over time. Read TMO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Thermo Fisher Scientific Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Thermo Fisher Scientific Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.56 Billion | 1.52% |
| Total Liquid Assets | $1.56 Billion | 1.52% |
Asset Resilience Insights
- Limited Liquidity: Thermo Fisher Scientific Inc maintains only 1.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Thermo Fisher Scientific Inc Industry Peers by Asset Resilience Ratio
Compare Thermo Fisher Scientific Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lonza Group AG
SW:LONN |
Diagnostics & Research | 3.04% |
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
Thermo Fisher Scientific Inc Asset Resilience Ratio by Year (1995–2024)
Thermo Fisher Scientific Inc asset resilience ratio by year from 1995 to 2024. The table below shows the annual Asset Resilience Ratio data for Thermo Fisher Scientific Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.72% | $5.57 Billion | $97.32 Billion | -0.47pp |
| 2023-12-31 | 6.19% | $6.11 Billion | $98.73 Billion | -2.59pp |
| 2022-12-31 | 8.78% | $8.53 Billion | $97.15 Billion | +4.07pp |
| 2021-12-31 | 4.71% | $4.48 Billion | $95.12 Billion | -10.29pp |
| 2020-12-31 | 14.99% | $10.35 Billion | $69.05 Billion | +10.82pp |
| 2019-12-31 | 4.17% | $2.44 Billion | $58.38 Billion | +0.43pp |
| 2018-12-31 | 3.75% | $2.11 Billion | $56.23 Billion | +1.37pp |
| 2017-12-31 | 2.37% | $1.34 Billion | $56.67 Billion | +0.63pp |
| 2016-12-31 | 1.75% | $802.00 Million | $45.91 Billion | +1.71pp |
| 2015-12-31 | 0.03% | $13.60 Million | $40.83 Billion | -0.03pp |
| 2014-12-31 | 0.07% | $28.70 Million | $42.85 Billion | +0.04pp |
| 2013-12-31 | 0.03% | $8.30 Million | $31.86 Billion | +0.01pp |
| 2012-12-31 | 0.02% | $4.30 Million | $27.44 Billion | 0.00pp |
| 2011-12-31 | 0.02% | $4.30 Million | $26.83 Billion | -0.03pp |
| 2010-12-31 | 0.04% | $8.90 Million | $21.39 Billion | +0.01pp |
| 2009-12-31 | 0.03% | $7.10 Million | $21.60 Billion | 0.00pp |
| 2008-12-31 | 0.04% | $7.50 Million | $21.09 Billion | -0.03pp |
| 2007-12-31 | 0.07% | $14.10 Million | $21.21 Billion | -0.16pp |
| 2006-12-31 | 0.23% | $48.16 Million | $21.26 Billion | -1.67pp |
| 2005-12-31 | 1.90% | $80.66 Million | $4.25 Billion | -3.29pp |
| 2004-12-31 | 5.18% | $185.37 Million | $3.58 Billion | +1.81pp |
| 2003-12-31 | 3.37% | $114.33 Million | $3.39 Billion | -11.34pp |
| 2002-12-31 | 14.71% | $536.43 Million | $3.65 Billion | -4.74pp |
| 2001-12-31 | 19.45% | $744.00 Million | $3.83 Billion | +8.74pp |
| 2000-12-31 | 10.71% | $521.00 Million | $4.86 Billion | -0.02pp |
| 1999-12-31 | 10.73% | $556.00 Million | $5.18 Billion | -7.45pp |
| 1998-12-31 | 18.18% | $1.15 Billion | $6.33 Billion | +2.15pp |
| 1997-12-31 | 16.03% | $929.00 Million | $5.80 Billion | -11.82pp |
| 1996-12-31 | 27.85% | $1.43 Billion | $5.14 Billion | +11.99pp |
| 1995-12-31 | 15.86% | $594.00 Million | $3.74 Billion | -- |
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines,… Read more